OIPE DEC 0 2 2005
WEMBERNOOT PTO

SUBSULT PTO-1449	Atty. Docket No.: 26473/04177	Serial No.: 10/039,753
APPLICANT'S INFORMATION DISCLOSURE STATEMENT		
	Applicant: Hazen, et al.	· ·
	Filing Date: January 2, 2002	Group: 3736 /644

U.S. PATENT DOCUMENTS

Initial*		Document No.	Date	Name	Class	Subcl.	Filing Date
PN	AA	5,731,208	March 24, 1998	Heinecke			Sep. 9, 1996
	AB	5,985,272	November 16, 1999	Deby, et al.			Dec. 31, 1996
	AC	6,096,556	August 1, 2000	Heinecke			Oct. 13, 1998
	AD	6,133,039	October 17, 2000	Heinecke			Jan. 18, 2000
	AE	6,953,666	October 11, 2005	Kinkade, Jr., et al.			Aug. 13, 2001
—	AF	2003/0119792	June 26, 2003	Roca			Sep. 30, 2002

FOREIGN PATENT DOCUMENTS

- /	7	Document No.	Date	Country	Class	Subcl.	Translation?
PN	AG ·	02/48715	June 20, 2002	WO			
	AH						
	AI					l	

OTHER PRIOR ART

0.1	AJ	"Primary Prevention of Acute Coronary Events with Lovastatin in Men and Women with Average			
PN		Cholesterol Levels" by Downs, et al., <u>JAMA</u> , May 27, 1998, Vol. 279, No. 20, pp. 1615-1622.			
	AK	"The Effect of Pravastatin on Coronary Events After Myocardial Infarction in Patients with Average			
)		Cholesterol Levels" by Sacks, et al., The New England Journal of Medicine, Vol. 335, No. 14, October 3, 1996			
ļ	1	pp. 1001-1009.			
	AL	"Byeond Cholesterol: Modifications of Low-Density Lipoprotein that Increase its Atherogenecity" by			
1		Steinberg, et al., The New England Journal of Medicine, Vol. 320, No. 14, April 6,1989, pp. 915-924.			
	AM	"Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors" by Takemoto, et al.,			
1		Arterioscler Throm Vasc Biol, 2001;21:1712-1719.			
	AN	"The Evolving Role of Statins in the Management of Atherosclerosis" by Vaughan, et al.,			
1		Journal of the American College of Cardiology, Vol 35, No. 1, 2000, pp. 1-10.			
j	AO	"Reduction of Plasma 24S-Hydroxycholesterol (Cerebrosterol) Levels Using High-Dosage Simvastatin in			
		Patients with Hypercholesterolemia" by Locatelli, et al., Arch Neurol, Vol. 59, Feb. 2002, pp. 213-216.			
	AP	"Alzehimer's Disease: Bad for the Heart, Bad for the Mind" by Marx, Science, Vol. 294, October 19, 2001,			
		pp. 508-509.			
	AQ	3-Hydroxy-3-methylglutaryl-coenzyme A reductase in mRNA in Alzheimer and control brain"			
İ		by Yasojima, et al., Clinical Neuroscience and Neuropathology, Vol. 12, No. 13, September 17, 2001,			
		pp. 2935-2938.			
	AR	"Lovastatin Treatment Decreases Mononuclear Cell Infiltration Into the CNS of Lewis Rats with			
1		Experimental Allergic Encephalomyelitis" by Stanislaus, et al., Journal of Neuroscience Research,			
1		66:155-162 (2001).			
V	AS	"Effect of Hydroxymethylglutaryl Coenzyme A Reductase Inhibitors on the Progression of Calcific			
		Aortic Stenosis" by Novaro, et al., Circulation, 2001; 104:2205-2209.			
Examiner:	P.N				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.

OIPE IN	\	62 . 4
DEC 0 2 2005	ر د د	DEC 0 2 2005
Cobsta Reico PTO	TO.	Cobst Foreign

Page 2 of 2 Serial No.: 10/039,753 Atty. Docket No.: 26473/04177 -1449 **AMMINIST INFORMATION APPLICANT'S** DISCLOSURE STATEMENT Applicant: Hazen, et al. Group 2736 √ Filing Date: January 2, 2002

U.S. PATENT DOCUMENTS

Initial*		Document No.	Date	Name	Class	Subci.	Filing Date
	AA						
	AB					<u> </u>	
	AC					<u> </u>	<u> </u>
	AD					<u> </u>	
	AE						
	AF						

FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Class	Subcl.	Translation?
AC						
AF						
AI						<u> </u>

OTHER PRIOR ART

PN	AJ	"Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events" by Ridker, et al., <u>The New England Journal of Medicine</u> , Vol. 344, No. 26, June 28, 2001, pp. 1959-1965.
PN.	ĄK	"Rapid Reduction in C-Reactive Protein with Cerivastatin Among 785 Patients with Primary Hypercholesterolemia" by Ridker, Circulation, 2001; 103:1191-1193.
PN	AL	"Are Statins Anti-Inflammatory? Issues in the Design and Conduct of the Pravastatin Inflammation C-Reactive Proetin Evaluation" by Ridker, et al., Current Cardiology Reports, 2000, 2:269-273.
	AM	
	AN	
	AO	
	AP	
	AQ	
	AR	
	AS	
Examiner:	P.	NOC Date Considered: 2/24/06

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.

	*	
Subst. Form PTO-1449	Atty. Docket No.: 26473/04177	Serial No.: 10/039,753
APPLICANT'S INFORMATION DISCLOSURE STATEMENT		
	Applicant: Hazen, et al.	
	Filing Date: January 2, 2002	Group: 3736 / 64/L/

U.S. PATENT DOCUMENTS

Initial*		Document No.	Date	Name	Class	Subcl.	Filing Date
	AA						
	AB						1
- "	AC						
	AD						

FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Class	Subcl.	Translation?
AE						
AF						
AG						
AH					<u> </u>	
AI						

OTHER PRIOR ART

PN	AJ	"Circulating Myeloperoxidase and Anti-Myeloperoxidase Antibody in Patients with Vasculitis" by Minota, et al., Scand J. Rheumatol, 1999;25:94-9.
	AK	
	AL	
	AM	
	AN	
	AO	
	AP	
	AQ	
	AR	
	0	<i>i</i>
Examiner:	Pas	Date Considered: D 2/24/06

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.